Anti-Human IgG, Pan [Clone HP6017] – FITC

Purified human immunoglobulins

This Fluorescein (FITC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.

Liquid

Research Use Only

2 – 8° C Wet Ice

Blue Laser (488 nm)

Clone HP6017 activity is directed against all four forms of human immunoglobulin gamma: IgG1, IgG2, IgG3 and IgG4. HP6017 cross-reacts with IgG from rabbit, goat, sheep, and horse.

Humans produce five classes of immunoglobulins, IgM, IgD, IgA, IgE, and IgG¹. IgG is the most abundant class¹ and functions in the humoral immune response². There are four subclasses of IgG, and they are numbered according to decreasing abundance as IgG1 through IgG4. The four subclasses are highly conserved and consist of four polypeptide chains: two identical heavy chains and two identical light chains¹. While the general structure is very similar between IgG subclasses, differences in their constant regions in the hinge and upper CH2 domain as well as in glycosylation affect their binding to antigens (e.g. pathogenic proteins, polysaccharides, allergens), C1q, and Fc receptors, leading to differences in functionality. As a result, each IgG subclass has a unique response skewed to specific antigens.

IgG1 is the most abundant subclass of IgG and is primarily induced by soluble protein antigens and membrane proteins¹. IgG2 responds to bacterial capsular polysaccharide antigens. IgG3 is a pro-inflammatory antibody that potently induces effector function. IgG4 is induced by repeated or chronic exposure to antigens that are non-infectious, such as allergens or antigens released during parasitic worm (helminth) infection.

HP6017 was generated by immunizing a BALB/c mouse with purified human immunoglobulins³. Spleen cells were fused with Sp2/0-Ag14 myeloma cells.

IgG is produced by B cells and is present in mucosal secretions and serum.

IgG-Fc receptors, C1q

IgG1: P0DOX5
IgG2: P01859
IgG3: P01860
IgG4: P01861

1 Vidarsson G, Dekkers G, Rispens T. Front Immunol. 5:520. 2014.
2 Rispens T, Huijbers MG. Nat Rev Immunol. 23(11):763-778. 2023.
3 Reimer CB, Phillips DJ, Aloisio CH, et al. Hybridoma. 3(3):263-275. 1984.
4 Jefferis R, Reimer CB, Skvaril F, et al. Immunol Lett. 10(3-4):223-252. 1985.
5 Hamilton RG, Wilson RW, Spillman T, et al. J Immunoassay. 9(3-4):275-296. 1988.